Responsiveness of experimental prostate carcinoma bone tumors to neutron or photon radiation combined with cytokine therapy

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 5, 2003, Pages 1426-1437

  Hillman, Gilda G ^a   Maughan, Richard L ^b   Grignon, David J ^a   Yudelev, Mark ^a   Che, Mingxin ^a   Abrams, Judith ^a   Wang, Yu ^a   Layer, Andrey ^a   Wright, Jennifer L ^a   Rubio, Johanna ^a   Forman, Jeffrey D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Interleukin 2; Mouse bone tumors; Radiation

Indexed keywords

BONE; HISTOLOGY; PHOTONS; RADIOTHERAPY;

FIBROSIS;

TUMORS;

CYTOKINE; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TUMOR; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMUR; FIBROSIS; HIP; HISTOLOGY; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; LIGHT; MOUSE; NEUTRON RADIATION; NONHUMAN; NUDE MOUSE; OSSIFICATION; PALPATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0038164988     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00438-3     Document Type: Article

References (25)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin. 50:2000;7-33.
2. Zietman A.L., Shipley W.U., Willett C.G. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer. 71:1993;959-969.
3. Hall E.J. Time, dose, and fraction in radiotherapy. Ryan J.D. Radiobiology for the radiobiologist. 1994;1-13 JB Lippincott Company, Philadelphia., 231-244.
4. Maughan R.L., Powers W., Blosser H.G. A superconducting cyclotron for neutron radiation therapy. Med Phys. 21:1994;779-785.
5. Maughan R.L., Blosser G.F., Blosser E.B., et al. A multirod collimator for neutron therapy. Int J Radiat Oncol Biol Phys. 34:1996;411-420.
6. Forman J.D., Tekyi-Mensah S., Caudrelier J.M. Neutron radiation in the management of localized and locally advanced prostate cancer. D'Amico A.V., Hanks G.E. Advances in the radiotherapeutic management of carcinoma of the prostate. 1998;73-89 Chapman and Hall, New York, NY.
7. Forman J. Neutron radiation for prostate cancer. Prostate J. 1:1999;8-14.
8. Haas G.P., Pontes J.E. Management of the urological patient. Sivak E. The high risk patient: Management of the critically ill patient. 1995;839-856 Lea and Febiger, Philadelphia, PA.
9. Redman B., Pienta J. New treatment strategies for hormone refractory prostate cancer. Semin Urol. 2:1995;164-169.
10. Jacobs S.C. Spread of prostatic cancer to bone. Urology. 21:1983;337-344.
11. Hillman G.G., Triest J.A., Cher M.L., et al. Prospects of immunotherapy for the treatment of prostate carcinoma - a review. Cancer Detect Prev. 23:1999;333-342.
12. Porter A.T., Benda R., Ben-Josef E. Palliation of metastases: Bone and spinal cord. Gunderson L.L., Tepper J.E. Clinical radiation oncology. 2000;299-311 Churchill Livingstone, Philadelphia.
13. Coleman R.E. Management of bone metastases. Oncologist. 5:2000;463-470.
14. Hillman G.G., Haas G.P., Wahl W.H., et al. Adoptive immunotherapy of cancer Biological response modifiers and cytotoxic cell therapy . Biotherapy. 5:1992;119-129.
15. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 85:1993;622-632.
16. Hillman G.G., Maughan R.L., Grignon D.J., et al. Neutron or photon irradiation for prostate tumors Enhancement of cytokine therapy in a metastatic tumor model . Clin Cancer Res. 7:2001;136-144.
17. Kaighn M.E., Narayan K.S., Ohnuki Y., et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:1979;16-23.
18. Kocheril S.V., Grignon D.J., Wang C.Y., et al. Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. Cancer Detect Prev. 23:1999;408-416.
19. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
20. Holm S. Simple sequential rejective multiple test procedure. Scand J Stat. 6:1979;65-70.
21. Hillman G.G., Forman J.D., Kucuk O., et al. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res. 7:2001;382-390.
22. Carrano A.V. Chromosome aberrations and radiation-induced cell death I. Transmission and survival parameters of aberrations. Mutat Res. 17:1973;341-353.
23. Vidair C.A., Chen C.H., Ling C.C., et al. Apoptosis induced by X-irradiation of rec-myc cells is postmitotic and not predicted by the time after irradiation or behavior of sister cells. Cancer Res. 56:1996;4116-4118.
24. Younes E., Haas G.P., Dezso B., et al. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol. 165:1995;243-251.
25. Dezso B., Haas G.P., Hamzavi F., et al. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma Histological evaluation of pulmonary metastases . Clin Cancer Res. 2:1996;1543-1552.